Evaluation of Glial and Neuronal Blood Biomarkers Compared With Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain Injury.

ABSTRACT:

Importance

In 2018, the combination of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase (UCH-L1) levels became the first US Food and Drug Administration-approved blood test to detect intracranial lesions after mild to moderate traumatic brain injury (MTBI). How this blood test compares with validated clinical decision rules remains unknown.

Objectives

To compare the performance of GFAP and UCH-L1 levels vs 3 validated clinical decision rules for detecting traumatic intracranial lesions on computed tomography (CT) in patients with MTBI and to evaluate combining biomarkers with clinical decision rules.

Design, setting, and participants

This prospective cohort study from a level I trauma center enrolled adults with suspected MTBI presenting withi

SUBMITTER: Papa L 

PROVIDER: S-EPMC9907341 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature